Exercise4

Rallybio Corp

Total Value

$219.7K

Filing Date

Oct 14, 2026

1 transactions

Trade Summary

On Oct 12, 2026, Hopfner Robert Lorne, Insider, reported $219.7K of Rallybio Corp (RLYB) across 1 transactions. The filing covers Common Stock and reflects balanced net activity of $0. Reported prices ranged from $2.38 to $15.28. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Insider Information

Name: Hopfner Robert Lorne
Role: Insider
Location: EAST BERLIN, CT

Filing Details

Filing Date: Oct 14, 2026
Transaction Date: Oct 12, 2026
Accession Number: 0001193125-26-421747
Form Type: 4

Non-Derivative Transactions

Date	Security	Shares	Price	Type	Value
Oct 12, 2026	Common Stock	9,196	$7.60	Exercise	$69.9K
Oct 12, 2026	Common Stock	3,562	$2.38	Exercise	$8.5K
Oct 12, 2026	Common Stock	2,062	$15.28	Exercise	$31.5K

Derivative Transactions

Date	Security	Shares	Exercise Price	Type	Value
Oct 12, 2026	RLYB derivative	9,196	$7.60	Exercise	$69.9K
Oct 12, 2026	RLYB derivative	3,562	$2.38	Exercise	$8.5K
Oct 12, 2026	RLYB derivative	2,062	$15.28	Exercise	$31.5K

Want live alerts when Hopfner Robert Lorne trades again?

Download Insider Trades to track RLYB, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)The option vests as to the underlying shares of Common Stock in 12 equal installments, each on the last day of each month of calendar year 2025.
(F2)This option was issued to the reporting person pursuant to the Company's 2021 Equity Incentive Plan in lieu of retainer fees of $51,500.
(F3)The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 13, 2026 or the date of the Company's 2026 Annual Meeting of Stockholders.
(F4)The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 15, 2025 or the date of the Company's 2025 Annual Meeting of Stockholders.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopfner Robert Lorne

(Last)

(First)

(Middle)

C/O RALLYBIO CORPORATION

PO BOX 325

(Street)

EAST BERLIN

06023

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Rallybio Corp [ RLYB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/12/2026		M		9,196	A	$7.6	9,196	D
Common Stock	10/12/2026		M		3,562	A	$2.38	12,758	D
Common Stock	10/12/2026		M		2,062	A	$15.28	14,820	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Option (Right to Buy)	$7.6	10/12/2026		M			9,196	⁽¹⁾	01/02/2035	Common Stock	9,196	$0.56⁽²⁾	0	D
Option (Right to Buy)	$2.38	10/12/2026		M			3,562	⁽³⁾	05/13/2035	Common Stock	3,562	$0	0	D
Option (Right to Buy)	$15.28	10/12/2026		M			2,062	⁽⁴⁾	05/15/2034	Common Stock	2,062	$0	0	D

Explanation of Responses:

1. The option vests as to the underlying shares of Common Stock in 12 equal installments, each on the last day of each month of calendar year 2025.

2. This option was issued to the reporting person pursuant to the Company's 2021 Equity Incentive Plan in lieu of retainer fees of $51,500.

3. The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 13, 2026 or the date of the Company's 2026 Annual Meeting of Stockholders.

4. The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 15, 2025 or the date of the Company's 2025 Annual Meeting of Stockholders.

	By: /s/ Jonathan Lieber, Attorney-in-Fact	10/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 4 as rendered by the SEC from accession 0001193125-26-421747.

Rallybio Corp

Trade Summary

Company Information

Insider Information

Filing Details

Non-Derivative Transactions

Derivative Transactions

Want live alerts when Hopfner Robert Lorne trades again?

Footnotes

SEC Form 4

SEC Filing

SEC Form 4